Association between ischemia-modified albumin, homocysteine, vitamin B12 and folic acid in patients with severe sepsis
dc.contributor.author | Erdem, Said Sami | |
dc.contributor.author | Yerlikaya, Fatma Humeyra | |
dc.contributor.author | Cicekler, Humeyra | |
dc.contributor.author | Gul, Mehmet | |
dc.date.accessioned | 2024-02-23T14:29:45Z | |
dc.date.available | 2024-02-23T14:29:45Z | |
dc.date.issued | 2012 | |
dc.department | NEÜ | en_US |
dc.description.abstract | Background: The aim of the present study was to investigate scrum ischemia-modified albumin (IMA), homocysteine, malondialdehyde (MDA), vitamin B-12 and folic acid levels in patients with severe sepsis, compared to healthy control subjects. Also, we examined associations of these parameters with high-sensitivity C-reactive protein (hsCRP) in patients with severe sepsis and healthy control subjects. Methods: This study was performed on 71 (40 male, 31 female) patients with severe sepsis aged 18-65 years and 70 (34 male, 36 female) healthy control subjects aged 18-65 years. Samples of patients were obtained at study entry within 24 h of onset of severe sepsis. Results: Serum IMA, homocysteine and MDA levels of the patients with severe sepsis were significantly higher than those of the healthy control subjects (p<0.0 I for IMA and homocysteine, and p<0.001 for MDA). There was no significant difference between serum vitamin B12 and folic acid levels of the groups. Serum hsCRP levels were positively correlated with IMA (p<0.01) and MDA (p<0.01) in the patients with severe sepsis. Conclusions: Our findings show that IMA may be useful as a prognostic biomarker because it can indicate the severity of illness in patients with sepsis. | en_US |
dc.identifier.doi | 10.1515/cclm-2011-0794 | |
dc.identifier.endpage | 1421 | en_US |
dc.identifier.issn | 1434-6621 | |
dc.identifier.issn | 1437-4331 | |
dc.identifier.issue | 8 | en_US |
dc.identifier.pmid | 22868807 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 1417 | en_US |
dc.identifier.uri | https://doi.org/10.1515/cclm-2011-0794 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12452/14848 | |
dc.identifier.volume | 50 | en_US |
dc.identifier.wos | WOS:000309200500019 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Walter De Gruyter Gmbh | en_US |
dc.relation.ispartof | Clinical Chemistry And Laboratory Medicine | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Folic Acid | en_US |
dc.subject | Homocysteine | en_US |
dc.subject | Ischemia-Modified Albumin | en_US |
dc.subject | Sepsis | en_US |
dc.subject | Vitamin B-12 | en_US |
dc.title | Association between ischemia-modified albumin, homocysteine, vitamin B12 and folic acid in patients with severe sepsis | en_US |
dc.type | Article | en_US |